The Food and Drug Administration is investigating serious adverse events involving Limbrel, a capsule being marketed as a medical food to manage the metabolic processes associated with osteoarthritis. Health care providers who know their patients are taking the product should advise them to stop taking it immediately, FDA said. While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis. For more information, see the FDA safety alert.

Related News Articles

Insights and Analysis
Also in this roundup of nursing news: two nurses save the life of a man struck by an SUV; and executive moves in the field.
Insights and Analysis
Also in this weekly roundup of nursing news: nurse leaders’ characteristics influence patient outcomes; a nurse helps a man who suffered a heart attack at the…
Headline
The Department of Health and Human Services Friday released guidance on its priorities for physician-focused payment models to help stakeholders who are…
Insights and Analysis
Also in this weekly roundup of nursing news: a talking robot may be poised to become an asset to nurses, and family-centered care interventions may reduce…
Insights and Analysis
Also in this weekly roundup of nursing news: A cancer survivor follows in the footsteps of the nurses who took care of her, and a small study suggests that…
Insights and Analysis
Also in this week’s roundup of nursing news: More to nurse staffing ratios than meets the eye; the media doesn’t show the full scope of nursing; and hospitals…